Retinalamin
Also known as: Retinalamine · Retinalamin (Geropharm) · bovine retina polypeptide complex · cattle retina cytamin · Citomedin / Cytamin (drug class) · polypeptide retinal bioregulator
Research focus
Retina and optic nerve — claimed retinoprotection/neuroprotection in retinal dystrophies, diabetic retinopathy, and glaucomatous optic neuropathy
US regulatory status
Not FDA-approved · Not compoundable
Evidence rating
Emerging
Origin
Retinalamin is not a synthetic short peptide but an extract drug: a complex of water-soluble polypeptide fractions isolated from the retinas of cattle (bovine retina). It belongs to the Russian "cytamin" / "citomedin" class of tissue-derived peptide preparations associated with the bioregulation school founded by Vladimir Khavinson at the St. Petersburg Institute of Bioregulation and Gerontology — the same lineage that produced Cortexin (brain), Thymalin (thymus), Epithalamin/Epitalon (pineal) and Prostatilen. The marketed product is manufactured in Russia (by Geropharm) and is registered there as an ophthalmic neuroprotective/retinoprotective agent. Khavinson-group reviews list Retinalamin among "peptide bioregulators as a new class of geroprotectors." Because it is a tissue extract rather than a chemically defined molecule, it carries no single amino-acid sequence; published characterization describes it as a mixture of low-molecular-weight peptides, which complicates standardization, batch comparison and independent verification of what the active species actually are.
Plain-language summary
Retinalamin is a Russian prescription drug made from a peptide extract of cattle retina, given by injection (into the muscle or near the eye) for retinal and optic-nerve diseases such as diabetic retinopathy and glaucoma. The idea is that it protects retinal nerve cells from damage. Unlike most peptides discussed on this hub, it is an actual registered medicine in Russia with several human studies behind it — including a couple of randomized trials in glaucoma — but nearly all of that research comes from Russian groups, is published in Russian, and has not been independently reproduced by Western labs. At least one animal experiment found no benefit at all. It is not approved in the United States, and the "research-chemical" versions sold online are not the registered drug and are not quality-verified. Treat the human evidence as early and one-sided, not settled.
Claimed mechanism (as reported)
The proposed mechanism is anti-excitotoxic, glutamate-mediated neuroprotection of retinal ganglion cells. Russian receptor-binding and biodistribution work reports that the polypeptide complex interacts with glutamate-receptor subtypes (AMPA, NMDA, mGluR1) implicated in ganglion-cell loss, and a retinal cell-culture study reported that adding the preparation alongside glutamate reduced glutamate's toxic effect in vitro. Khavinson-group authors additionally propose the broader "short peptide" model in which constituent peptides bind promoter regions of DNA and modulate gene expression to favor retinal-cell differentiation and survival. All of this is hedged: the active species are not chemically defined, the gene-expression/DNA-binding model is supported mainly by in-silico and in-vitro work from a single research school, and at least one controlled animal study reportedly found no neuroprotective effect — so the mechanism should be read as proposed, not established.
Evidence summary
Compared with most synthetic Cytogen peptides — which have essentially no human data — Retinalamin sits at the higher end of this hub's evidence ladder because it is a registered Russian drug with a real, if narrow, clinical literature, including at least two randomized controlled trials in primary open-angle glaucoma reporting slowed structural/functional decline at stable intraocular pressure. It is graded only "Emerging," not "Strong," for serious reasons: the body of work is almost entirely single-country (Russian), largely Russian-language, frequently industry-affiliated (Geropharm authors appear on several papers), heterogeneous in design, and not independently replicated in peer-reviewed English-language trials. Crucially, the evidence is not uniformly positive — a controlled rabbit model of photochemical retinal damage reportedly found no significant neuroprotective effect, and the active molecular species remain undefined. No large, multinational, independently-replicated RCT establishing clinical benefit exists as of 2026, and none of this constitutes FDA-recognized proof of efficacy or safety. A multi-source review beyond PubMed added a 2017 Russian meta-analysis of retinoprotective therapy (pooling ~11 Russian RCTs in dry AMD), a 2015 multicenter randomized trial in rhegmatogenous retinal detachment (n=85), and a large uncontrolled post-marketing series (n=4,172) — all open-label/non-blinded and single-country, so the strongest indications remain AMD and glaucoma while retinitis pigmentosa and diabetic retinopathy rest on uncontrolled data. No trials are registered on ClinicalTrials.gov.
What the research reports
Long-term retinal protective therapy and glaucoma progression by structural and functional tests (randomized controlled study)
Grade CStrakhov VV, Egorov EA, Erichev VP, Yartsev AV, Petrov SYu, Dorofeev DA · Vestnik Oftalmologii · 2019–2020
Reported finding: In patients with early-to-moderate primary open-angle glaucoma and compensated intraocular pressure, repeated Retinalamin courses were reported to stabilize visual-field and retinal-nerve-fiber-layer parameters relative to untreated controls. Reported from Russian centers without independent replication; authors note longer-term study is needed.
Sample: n=147 (249 eyes) and n=180 (355 eyes) in two POAG trials
Methodology: C — single-country randomized controlled trials (n=147 and n=180), unblinded/open design, Russian-language, no independent Western replication
Limitations: Single country, open-label, surrogate (structural/functional) endpoints rather than long-term vision outcomes, some author affiliations with the manufacturer.
Retinoprotective effects of Retinalamin in an experimental model of photochemical damage to rabbit retinas
Grade DSuetov AA, Alekperov SI, Odinokaya MA, Kostina AA · Vestnik Oftalmologii · 2021
Reported finding: Reported NO significant functional or morphological evidence of a neuroprotective effect of Retinalamin in this photochemical retinal-damage model: groups receiving the drug did not differ significantly from controls on electroretinography or histology. An important counterweight to positive clinical reports.
Sample: 36 rabbits (72 eyes), randomized into 4 groups
Methodology: D — controlled preclinical (animal) study; relevant as a NEGATIVE result
Limitations: Animal model, single study; null result not necessarily generalizable, but directly tempers efficacy claims.
Receptor (ligand–receptor) interaction and biodistribution of cattle retinal polypeptides; retinal ganglion cell culture under glutamate excitotoxicity
Grade DVerlov NA, Dorotenko AR, Trashkov AP et al.; Avetisov SE, Erichev VP, Yaremenko TV et al. · Vestnik Oftalmologii · 2019–2021
Reported finding: Radioligand-binding work reported interaction of the polypeptide drug with glutamate-receptor subtypes (AMPA, NMDA, mGluR1) and brain/eye biodistribution after injection; a separate cell-culture study reported that co-adding the preparation with glutamate increased viable-cell counts versus glutamate alone, interpreted as an anti-excitotoxic signal. Mechanistic and preclinical only.
Sample: Laboratory animals and cultured retinal cells (no defined human n)
Methodology: D — in-vitro / animal mechanistic studies, single research network
Limitations: In-vitro/animal, no chemically defined active species, single research network, does not demonstrate clinical efficacy.
Peptide bioregulators as a new class of geroprotectors — clinical studies (review listing Retinalamin) and molecular aspects of peptide retinoprotectors
Grade CKhavinson VKh, Kuznik BI, Ryzhak GA; Khavinson V, Trofimova S, Trofimov A, Solomin I · Advances in Gerontology (Uspekhi Gerontologii); Stem Cell Reviews and Reports · 2013–2019
Reported finding: Khavinson-group reviews summarize decades of Russian work positioning Retinalamin (with Cortexin, Thymalin, Epithalamin, Prostatilen) as a retinoprotective peptide bioregulator and propose a DNA/gene-expression mechanism for short peptides. Useful as primary-source context, but self-authored by the originators and not independent verification.
Sample: Not applicable (reviews)
Methodology: C/D — narrative reviews from the originating research school, not independent trials
Limitations: Author-affiliated reviews, English abstracts of Russian work, no blinding or external replication; describe a research program, not confirmed clinical proof.
Efficacy of Retinalamin in the complex treatment of rhegmatogenous retinal detachment (multicenter randomized trial)
Grade CAstakhov YuS, Belova TV, Boiko EV et al. · Ophthalmology Journal (Oftal’mologicheskie Vedomosti); indexed on CyberLeninka · 2015
Reported finding: Adding Retinalamin to standard management of rhegmatogenous retinal detachment was reported to improve functional recovery versus conservative treatment.
Sample: n=85 (85 eyes), treated vs conservative control
Methodology: C — multicenter randomized controlled but open-label/non-blinded, modest n
Limitations: Open-label, single-country, modest sample; surrogate visual-function endpoints.
Retinalamin for various ophthalmic disorders: large post-marketing observational experience
Grade DEgorov EA · RMJ Clinical Ophthalmology; indexed on CyberLeninka · 2017
Reported finding: A large uncontrolled observational series reported favorable tolerability and clinician-assessed outcomes across several retinal indications.
Sample: n=4,172 (dry/wet AMD, primary open-angle glaucoma, diabetic retinopathy, myopic disease)
Methodology: D — large but uncontrolled post-marketing case series (no comparator, no randomization)
Limitations: No control group or randomization; observational/post-marketing design cannot establish efficacy; manufacturer-adjacent.
Administration reported in studies
In the Russian clinical literature, Retinalamin is described as a lyophilized powder reconstituted in sterile saline and given as a course of injections — most commonly 5 mg intramuscularly once daily for about 10 days, sometimes as parabulbar/retrobulbar (peri-ocular) injection, with courses repeated every 3 to 6 months in chronic conditions such as glaucoma. Preclinical work used weight-based dosing in animals (e.g., roughly 0.25 mg/kg parabulbar in rabbits, ~1.7 mg/kg systemic in biodistribution studies). This is a summary of research conditions — not a dosing recommendation and not a protocol endorsed by TPC.
This section reports what published studies describe. It is not a dosing recommendation from TPS.
Safety record
Within the Russian clinical reports, Retinalamin is generally described as well tolerated over short injection courses, and an in-vitro cytotoxicity screen reported no significant toxicity to cultured cells across the tested concentration range. However, these tolerability claims come from the same single-country literature that reports the efficacy, are not backed by independent long-term pharmacovigilance in English-language sources, and do not address risks specific to a bovine (animal-tissue-derived) injectable — including immunogenicity/allergic potential, batch-to-batch variability, and theoretical concerns about animal-sourced biologics. Peri-ocular injection itself carries procedural risk. Claims of complete safety or freedom from side effects are not supportable; the safety picture outside Russia is essentially unverified, and the unregulated "research chemical" versions sold online are not the registered, quality-controlled drug.
US legal status
Not FDA-approved for any use. Not on the FDA 503A compoundable bulk drug substances list, and not legally compoundable for human clinical use in the United States. It is a foreign (Russian-registered) drug with no US marketing authorization. Any material sold online in the US as "Retinalamin" is offered only as a "research chemical" — that channel is unregulated, the product is not verified to be the registered drug, and it is not quality-checked by TPC.
Open research questions
- ? Can the glaucoma and diabetic-retinopathy findings be reproduced in large, properly blinded, multinational randomized controlled trials run by groups with no manufacturer affiliation — and do they hold up against the null preclinical result?
- ? What are the actual active peptide species in this bovine retina extract, and can batches be standardized well enough for reproducible pharmacology?
- ? Does any benefit translate to patient-meaningful long-term vision outcomes, or only to surrogate structural/electrophysiological markers measured over months?
- ? What is the real long-term and immunologic safety profile of a repeatedly injected animal-tissue-derived peptide complex, assessed by independent pharmacovigilance outside Russia?
Get new bioregulator research as it publishes
Summaries of the Russian and English-language literature, bias-checked and plainly framed.
Subscribe Free →